Posted by Michael Wonder on 21 Jul 2023
Emergent BioSolutions receives US FDA approval of Cyfendus (anthrax vaccine adsorbed, adjuvanted), previously known as AV7909, a two dose anthrax vaccine for post-exposure prophylaxis use
20 July 2023 - Emergent has been delivering Cyfendus vaccine to the US Department of Health and Human Services since 2019, under pre-emergency use authorisation status, and will continue to work with the US Government to transition to post-approval procurement
Emergent BioSolutions announced today that the US FDA has approved Cyfendus (anthrax vaccine adsorbed, adjuvanted), previously known as AV7909, for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis in persons 18 through 65 years of age when administered in conjunction with recommended anti-bacterial drugs.
